YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A financing round of €15 million from an Austrian private trust. The proceeds will be used to further develop YGION's unique YGNITE^TM technology platform and advance the lead program YG-01 into preclinical and clinical development.

Founded in 2022, YGION's high-profile team of experienced biotech veterans and entrepreneurs are focused on developing individualized "plug-and-play" cancer vaccines through a proprietary suite of technologies to identify, produce and target the delivery of relevant peptide neoepitopes resulting in safe, exceptionally potent, and precise targeted activation of the patient's immune system.

"We are on the cusp of a breakthrough in individualized cancer treatments" said Dr. Wolfgang Fischl, Chief Executive Officer of YGION. "This financing is truly exciting for YGION as we see it as a strong validation of our unique approach, and we are grateful for the support of our investors enabling us to take a significant step towards clinical validation of our technology. With the continued demonstration of the efficacy of our approach, we are open to additional investors and collaborators interested in our ground-breaking approach."

"We are confident that with our technology, we can realize the promise of simple, safe and effective cancer vaccines" added Dr. Geert Mudde, Chief Technology Officer of YGION. "Our YGNITE^TM platform gives us the unique ability to identify, select and synthesise relevant neoantigens, and combined with our CARGONAUT^TM immune-modulating carrier induces a powerful cell-mediated tumor specific response that targets and eliminates malignant cells with unmatched safety."

YGION's lead program YG-01 is currently in preclinical development.